Zymeworks Inc.

Contributing Author

Recent Articles by Zymeworks Inc.

Sep-02	Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager ZYME GlobeNewswire
Aug-19	Zymeworks Announces Participation in Upcoming Investor Conferences ZYME GlobeNewswire
Aug-11	Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry ZYME GlobeNewswire
Aug-07	Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results ZYME GlobeNewswire
Jul-28	Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate ZYME GlobeNewswire
Jul-17	Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 ZYME GlobeNewswire
May-30	Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer ZYME GlobeNewswire
May-22	Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences ZYME GlobeNewswire
May-21	Zymeworks Announces Participation in Upcoming Investor Conferences ZYME GlobeNewswire
May-19	Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference ZYME GlobeNewswire
May-08	Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results ZYME GlobeNewswire